Indications for: XOPENEX CONCENTRATE
Initially 0.63mg by nebulization 3 times daily at 6–8hr intervals; may increase to 1.25mg 3 times daily.
<6yrs: not established. 6–11yrs: 0.31mg by nebulization 3 times daily; max 0.63mg 3 times daily.
XOPENEX CONCENTRATE Warnings/Precautions:
Do not exceed recommended dose. Monitor for increased need; if inadequate control, reevaluate and consider adding an antiinflammatory (eg, corticosteroids). Sensitivity to sympathomimetics. Discontinue if paradoxical bronchospasm, cardiovascular effects, or hypersensitivity reactions occur. Cardiovascular disorders (esp. coronary insufficiency, arrhythmias, hypertension). Seizure disorders. Diabetes. Hyperthyroidism. Hypokalemia. Renal impairment; monitor (esp. in elderly). Elderly. Labor & delivery. Pregnancy. Nursing mothers.
XOPENEX CONCENTRATE Classification:
XOPENEX CONCENTRATE Interactions:
Avoid within 2 weeks of MAOIs, tricyclic antidepressants. Avoid other short-acting sympathomimetic aerosol bronchodilators, epinephrine. Antagonized by β-blockers. Caution with other drugs that may lower serum potassium (eg, diuretics). Monitor digoxin.
Accidental injury, bronchitis, dizziness, pharyngitis, rhinitis, vomiting, palpitations, chest pain, tachycardia, headache, tremor, nervousness.
Generic Drug Availability:
Vials (YES); HFA (NO)
Inhaler w. actuator (200 inh)—15g; Soln 0.31mg/3mL, 0.63mg/3mL, 1.25mg/3mL—24 vials; Concentrate 1.25mg/0.5mL—30 vials